--- title: "CJC-1295 with DAC: Dosing & Vendor Prices | BodyHackGuide" url: https://www.bodyhackguide.co/compound/cjc-1295-dac description: "CJC-1295 with DAC: dosing protocols, mechanism & side effects. Compare 4 current vendor prices." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Image: CJC-1295 with DAC molecular structure (https://www.bodyhackguide.co/assets/peptide-structure-placeholder-DUmZBF_j.png) # CJC-1295 with DAC Growth Hormone / IGF-1 Axis (https://www.bodyhackguide.co/wiki#cat-growth-hormone-/-igf-1-axis)Phase 2 Also known as: CJC w/ DAC, CJC DAC CJC-1295 with DAC (Drug Affinity Complex) is a modified form of CJC-1295 that incorporates a maleimidopropionic acid (MPA) reactive group at the C-terminus. Once injected, this MPA group forms a covalent thioether bond with free cysteine residues on serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. The pharmacokinetic consequence is dramatic. Image: Ion Peptide logo (https://ionpeptide.com/wp-content/uploads/2025/08/ion-peptide-logo-1-300x148.jpg) Featured vendor $11.80/mg $59.00 for 5mg at Ion Peptide · Buy at Ion Peptide: https://ionpeptide.com/product/cjc-1295-with-dac-5mg/?ref=reddit15 Half-life: 6–8 days (due to albumin binding via DAC) Route: Subcutaneous MW: ~3647 Da CAS: 863288-34-0 Last reviewed: May 4, 2026 ## Overview ### At A Glance Mechanism CJC-1295 with DAC has the same pharmacodynamic mechanism as the non-DAC variant (GHRH receptor agonism on pituitary somatotrophs) but radically different pharmacokinetics.… Half-Life 6–8 days (due to albumin binding via DAC) Dosing Once per week Dose Range 1,000–2,000 mcg (1–2 mg) per injection Routes Subcutaneous Common Vials 2mg 5mg Potential Benefits Sustained IGF-1 elevation (1.5-3x baseline) for 28+ days Convenient weekly subcutaneous dosing Improved body composition (lean mass, fat loss) Enhanced recovery from training and injury Albumin conjugation extends half-life to ~8 days Stimulates endogenous GH production vs exogenous replacement Dose-dependent GH elevation 2-10x baseline Phase 1 clinical data in 50 healthy adults (Teichman 2006) Useful in compounding pharmacy GH-axis protocols Single-agent convenience vs combination peptide protocols Safety Notes Common Water retention Headache Injection site reactions Increased appetite ### Mechanism of Action CJC-1295 with DAC has the **same pharmacodynamic mechanism** as the non-DAC variant (GHRH receptor agonism on pituitary somatotrophs) but radically different pharmacokinetics. **1. Albumin conjugation - the central pharmacokinetic feature** - The MPA (maleimidopropionic acid) group is highly reactive toward free thiol groups - Serum albumin contains one free cysteine (Cys-34) per molecule - Within hours of SC injection, CJC-1295 DAC forms a **covalent thioether bond with Cys-34 on serum albumin** - The conjugate circulates for the full albumin half-life (~20 days) - Effective drug half-life: **~8 days** (shorter than albumin because GHRH portion is slowly cleaved/metabolized) **2. Sustained GHRH-receptor activation** Because the albumin-bound conjugate keeps GHRH-active peptide in circulation for days, the pituitary GHRH receptor is **continuously exposed to ligand** rather than to brief, widely spaced pulses. Critically, this does **not** abolish pulsatile GH release: in the controlled pharmacodynamic work, pulsatile GH secretion _persisted_ during continuous stimulation with CJC-1295 (Ionescu & Frohman, 2006, _J Clin Endocrinol Metab_). What shifts is the baseline - DAC raises **trough (basal) and mean GH** concentrations while the underlying pulse frequency is largely preserved. The practical consequences: - Higher basal and mean GH, with pulsatility retained rather than eliminated - A sustained **IGF-1 plateau** rather than the sharp IGF-1 swings of short-acting secretagogues - A theoretical risk of partial receptor desensitization with chronic, continuous exposure **3. Pharmacokinetic profile (Teichman Phase 1 data)** Single 60 mcg/kg SC dose: - GH levels: 2-10x baseline, sustained for 6-14 days - IGF-1: 1.5-3x baseline, sustained for up to 28 days with repeated weekly dosing - IGFBP-3 proportionally elevated **4. No direct ghrelin-receptor activity** DAC does not bind GHS-R1a. If stacking with ipamorelin is desired, the two must be dosed separately - DAC weekly, ipamorelin daily. Many practitioners skip ipamorelin when using DAC because the sustained GH elevation already approaches pituitary capacity. **5. Downstream IGF-1 axis effects** - Hepatic JAK2/STAT5 signaling produces sustained IGF-1 mRNA transcription - IGFBP-3 rises proportionally (binds 90% of circulating IGF-1) - Free (bioactive) IGF-1 rises modestly - Tissue IGF-1 (muscle, bone, cartilage) rises more substantially **6. What's different vs MOD-GRF 1-29 (without DAC)** | Parameter | CJC-1295 DAC | MOD-GRF 1-29 | | --- | --- | --- | | Half-life | ~8 days | ~30 min | | GH profile | Raised basal GH, pulses preserved | Discrete pulses, low basal | | IGF-1 magnitude | 1.5-3x baseline | 1.5-2x baseline | | Dose frequency | Weekly | 2-3x daily | | Receptor desensitization risk | Higher | Lower | | Physiologic mimicry | Lower | Higher | | Ipamorelin synergy | Limited (timing mismatch) | Strong | This is why modern protocols favor the non-DAC form despite its inconvenience. ### Overview CJC-1295 with DAC (Drug Affinity Complex) is a modified form of CJC-1295 that incorporates a **maleimidopropionic acid (MPA) reactive group** at the C-terminus. Once injected, this MPA group forms a **covalent thioether bond with free cysteine residues on serum albumin**, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. The pharmacokinetic consequence is dramatic. Native GHRH has a half-life of <2 minutes. MOD-GRF 1-29 (CJC-1295 without DAC) has a half-life of ~30 minutes. **CJC-1295 with DAC has a half-life of ~8 days** and produces sustained IGF-1 elevation for up to 28 days after a single injection (Teichman et al., 2006, _J Clin Endocrinol Metab_ (https://pubmed.ncbi.nlm.nih.gov/16352683/)). This makes DAC the **weekly-dosing variant**: one subcutaneous injection of 1-2 mg per week, typically on the same day each week. Convenience is its headline advantage over MOD-GRF 1-29's 2-3x daily injections. The trade-off is physiologic. DAC produces **continuous, non-pulsatile GH elevation** rather than the sharp pulses of natural secretion or MOD-GRF 1-29. In Teichman's Phase 1 trial, mean GH levels at 60 mcg/kg rose 2-10 fold above baseline and **remained elevated continuously for 6-14 days** after a single injection, with IGF-1 rising 1.5-3 fold and staying elevated for up to 28 days with repeated weekly dosing. This is an efficient way to raise IGF-1 but is not how the body normally operates. Clinical development was halted at Phase 2 — ConjuChem Biotechnologies did not publicly detail the reason, though industry commentary has pointed to concerns about sustained non-pulsatile GH elevation, insulin resistance, and the general challenges of bringing a GH-axis drug to market. Tesamorelin (a shorter-acting GHRH analog) became the FDA-approved GHRH analog for HIV-associated lipodystrophy instead. CJC-1295 with DAC is **not FDA-approved** and is used research-only or through compounding pharmacies. It is the less-favored of the two CJC-1295 forms in modern clinical protocols; most practitioners now prefer MOD-GRF 1-29 (without DAC) stacked with ipamorelin for the more physiologic pulsatile profile. See /compound/cjc-1295 (https://www.bodyhackguide.co/compound/cjc-1295) for the non-DAC variant, and our Reconstitution Tool (https://www.bodyhackguide.co/tools/reconstitution/cjc-1295) for injection math. ### Potential Research Fields Growth hormone axis Long-acting peptide therapeutics Body composition Anti-aging medicine Albumin-drug conjugation chemistry Endocrinology Compounding pharmacy ## Chemical Information IUPAC Name CJC-1295 with Drug Affinity Complex CAS Number 863288-34-0 Molecular Formula C165H271N47O46 Molecular Mass 3647.1 g/mol Image: CJC-1295 with DAC molecular structure (https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/91810141/PNG?image_size=300x300) View on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/91810141 Amino Acid Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH2 - a 30-residue tetra-substituted analog of human GRF(1-29): [D-Ala2, Gln8, Ala15, Leu27] substitutions (the "modified GRF 1-29" backbone), plus a C-terminal Lys30 bearing a maleimidopropionyl (MPA) "DAC" linker that forms a covalent thioether bond with Cys-34 of serum albumin. ## Dosing & Protocols ### Unlock the dosing protocols Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser. - Dose, route, how often and how long - A titration schedule - Beginner, intermediate and advanced protocols - Reconstitution and handling notes You also get the free peptide cheat sheet by email. Unsubscribe anytime. Have an account? Sign in (https://www.bodyhackguide.co/auth) ## Research ### Unlock the research summary - A summary of the key research - Safety and side effects - A link to the PubMed results ## Interactions ### Interaction Matrix ### Contraindications **Absolute contraindications** - **Active malignancy of any type** — sustained IGF-1 elevation is a stronger pro-tumorigenic concern than with pulsatile MOD-GRF 1-29 - **History of cancer within 5 years** — relative; discuss with oncologist - **Diabetic retinopathy (active or history)** - **Pregnancy and lactation** - **Children with open growth plates** - **Critical illness requiring ICU care** — Takala 1999 signal of increased mortality with sustained GH - **Severe uncontrolled type 2 diabetes (HbA1c >8)** — sustained GH worsens glucose **Relative contraindications** - Controlled type 2 diabetes — use non-DAC form preferentially - Obstructive sleep apnea - Severe hypothyroidism - Intracranial pathology - Family history of acromegaly or pituitary adenoma **Drug interactions** - **Glucocorticoids** — may blunt response; minimize - **Somatostatin analogs** — direct GH suppression; incompatible - **Insulin / insulin secretagogues** — counter-regulatory; monitor glucose - **Oral estrogens (high-dose)** — blunt hepatic IGF-1 response - **Chemotherapy agents** — avoid concurrent use **Surgery considerations** - Hold 2-3 weeks before elective major surgery (due to longer washout) - Disclose to all clinicians, especially oncology, endocrinology, ophthalmology - Washout from DAC is 3-4 weeks due to ~8-day half-life plus albumin half-life **WADA prohibition** - GH-releasing peptides prohibited at all times for competitive athletes - Urine testing can detect GH-axis manipulation via GH isoform ratios and IGF-1 measurements **Disclosure obligations** - All clinicians - Insurance applications (material in some jurisdictions) - Workers' compensation / disability evaluations **Cannot be rapidly reversed** Because of the 8-day half-life and 3-4 week washout, CJC-1295 with DAC cannot be rapidly discontinued in response to an acute side effect or contraindication change. Users and clinicians must be prepared for this. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $34.99 up to $59.99 Best $/mg $7.9980 Vendors 4 Listings 6 vial Dosage Form Sort | Vendor | Product | Form | Qty | Price | $/mg | Coupon | | | --- | --- | --- | --- | --- | --- | --- | --- | | Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🇪🇺 EU 🇬🇧 UK | CJC-1295 with DAC | vial | 1 vial ● In Stock | $59.99 | — | — | Buy: https://disguisedalpha.com/product/cjc-1295-drug-affinity-complex/?coupon=reddit | | Image: Ion Peptide logo (https://ionpeptide.com/wp-content/uploads/2025/08/ion-peptide-logo-1-300x148.jpg) Ion Peptide (https://www.bodyhackguide.co/vendors/ion-peptide) 70: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🌍 International | CJC-1295 With DAC 5mg | vial | 1 vial ● In Stock | $59.00 | $11.80 | — | Buy: https://ionpeptide.com/product/cjc-1295-with-dac-5mg/?ref=reddit15 | | Image: BioMyst Labs logo (https://biomystlabs.com/wp-content/uploads/2025/12/Asset-36@3x-scaled.png) BioMyst Labs (https://www.bodyhackguide.co/vendors/biomyst-labs) 70: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🌍 International | CJC-1295 w/ DAC 5mg | vial | 1 vial ● In Stock | $39.99 VALUE | $8.00 | — | Buy: https://biomystlabs.com/product/cjc-w-dac-5mg/?ref=rxtkqorwv | | Image: BioMyst Labs logo (https://biomystlabs.com/wp-content/uploads/2025/12/Asset-36@3x-scaled.png) BioMyst Labs (https://www.bodyhackguide.co/vendors/biomyst-labs) 70: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🌍 International | CJC-1295 w/ DAC 5mg | vial | 1 vial ● In Stock | $44.99 | $9.00 | — | Buy: https://biomystlabs.com/product/cjc-w-dac-5mg/?ref=rxtkqorwv | | Image: VANDL Labs logo (https://halfnattys.shop/wp-content/themes/halfnattys/assets/img/logo.webp) VANDL Labs (https://www.bodyhackguide.co/vendors/vandl-labs) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | CJC w/ DAC 2mg | vial | 2mg vial ● In Stock | $34.99 BEST | $17.50 | CHON | Buy: https://www.vandl-labs.com/product/cjc-w-dac/?ref=choncho | | Image: VANDL Labs logo (https://halfnattys.shop/wp-content/themes/halfnattys/assets/img/logo.webp) VANDL Labs (https://www.bodyhackguide.co/vendors/vandl-labs) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | CJC w/ DAC 5mg | vial | 5mg vial ● In Stock | $49.99 | $10.00 | CHON | Buy: https://www.vandl-labs.com/product/cjc-w-dac/?ref=choncho | ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with CJC-1295 with DAC. Current low $34.99 current listings 7-day low — not enough history yet 30-day low — not enough history yet 30-day change — not enough history yet Tracking since Mar 13, 2026 · 5 data points ## Price History 4 data points ### Vendors Selling CJC-1295 with DAC #### VANDL Labs 2 listings · from $34.99 https://www.bodyhackguide.co/vendors/vandl-labs #### BioMyst Labs 4.5 2 listings · from $39.99 https://www.bodyhackguide.co/vendors/biomyst-labs #### Ion Peptide 4.5 1 listing · from $59.00 https://www.bodyhackguide.co/vendors/ion-peptide #### Disguised Alpha 1 listing · from $59.99 https://www.bodyhackguide.co/vendors/disguised-alpha How we score these vendors Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. View Scorecard (https://www.bodyhackguide.co/vendors/scorecard) ### Related Compounds View All (https://www.bodyhackguide.co/wiki) ### CJC-1295 (Mod GRF 1-29) Growth Hormone / IGF-1 Axis Preclinical CJC-1295 without DAC (also called Modified GRF 1-29 or MOD-GRF 1-29) is a 30-amino-acid analog of the first 29 residues of endogenous Growth Hormone Releasing Hormone (GHRH), with four strategic substitutions (D-Ala² for DPP-4 resistance, Gln⁸, Ala¹⁵, Leu²⁷) that extend its plasma half-life from <2 minutes (native GHRH) to ~30 minutes. t½ ~30 minutes (without DAC / MOD-GRF 1-29); ~6-8 days (with DAC, due to covalent albumin binding) Without DAC: 100-300 mcg subcutaneous 1-3x daily (typically pre-bedtime); With DAC: 1000-2000 mcg subcutaneous once weekly 29 PubMed View Profile https://www.bodyhackguide.co/compound/cjc-1295 ### CJC-1295 with DAC Growth Hormone / IGF-1 Axis Preclinical / Research peptide CJC-1295 with DAC is the long-acting variant of CJC-1295. t½ ~6-8 days (DAC-bound albumin depot) 1000-2000 mcg (1-2 mg) per week Preclinical View Profile https://www.bodyhackguide.co/compound/cjc-1295-with-dac ### GHRP-2 Growth Hormone / IGF-1 Axis Phase 2 GHRP-2 (growth hormone-releasing peptide-2), also known as pralmorelin and KP-102, is a synthetic hexapeptide growth hormone secretagogue that was among the first GHRPs developed in the seminal research of Cyril Bowers and colleagues at Tulane University in the late 1980s and early 1990s. t½ ~15-30 minutes 100–300 mcg per injection 212 PubMed View Profile https://www.bodyhackguide.co/compound/ghrp-2 ### GHRP-6 Growth Hormone / IGF-1 Axis Phase 2 GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 that binds the ghrelin receptor (GHS-R1a) to stimulate endogenous growth hormone release. t½ ~20–30 minutes 100–300 mcg per injection 156 PubMed View Profile https://www.bodyhackguide.co/compound/ghrp-6 ### Hexarelin Growth Hormone / IGF-1 Axis Phase 2 Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. t½ ~55 minutes (IV, per Imbimbo 1994) 100–200 mcg per injection 14 PubMed View Profile https://www.bodyhackguide.co/compound/hexarelin ### IGF-1 LR3 Growth Hormone / IGF-1 Axis Phase 2 IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of human insulin-like growth factor 1 modified at two positions to dramatically extend its serum half-life and amplify its tissue bioactivity compared to native IGF-1. t½ 20-30 hours (community/vendor estimate; no published human PK study of IGF-1 LR3) vs ~12 minutes for native IGF-1 20-80 mcg per day 40 PubMed View Profile https://www.bodyhackguide.co/compound/igf-1-lr3 ### Side-by-Side Comparisons All Comparisons (https://www.bodyhackguide.co/compare) CJC-1295 with DAC vs CJC-1295 (Mod GRF 1-29): https://www.bodyhackguide.co/compare/cjc-1295-dac-vs-cjc-1295 View Full Dosage Guide → Protocols, calculator & safety for CJC-1295 with DAC https://www.bodyhackguide.co/guides/dosage/cjc-1295-dac ### Related Articles All Posts (https://www.bodyhackguide.co/blog) #### CJC-1295 and Ipamorelin: A Complete Research Reference CJC-1295 is a GHRH analog that raises the growth-hormone "signal," while Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist that amplifies the GH pulse. Researchers pair them because they act on two different but complementary pathways at once. These are research compounds only, not for human use, and most of the supporting evidence is preclinical or early-stage. 7/1/2026 https://www.bodyhackguide.co/blog/cjc-1295-ipamorelin-guide #### The Complete Peptide Reconstitution Guide (2026): Ratios, Math, and Common Mistakes The master reconstitution reference for 17 peptides. BAC vs SWFI vs acetic acid, mg/mL targets, IU math on U100 syringes, storage and stability by peptide class, sterile technique, and the mistakes that destroy $60 vials. Includes worked examples for BPC-157, TB-500, GHK-Cu, semaglutide, tirzepatide, CJC-1295, ipamorelin, sermorelin, GHRPs, Melanotan II, PT-141, oxytocin, Semax, Selank, DSIP, and epithalon. 4/21/2026 https://www.bodyhackguide.co/blog/complete-peptide-reconstitution-guide-2026 ### Featured Price Ion Peptide $59.00($11.80/mg) 4 vendors · 6 listings ### Research Score 60 0 PubMed results ### Quality Indicators Data Completeness 88% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Results Interactions Vendor Listings ### Quick Facts Half-Life Molecular Weight 3647.1 g/mol Administration Subcutaneous CAS Number 863288-34-0 Trial Phase Phase 2 ### Safety Profile Low Risk Common Side Effects - • Water retention - • Headache - • Injection site reactions - • Increased appetite Stop Use If - Active malignancy - Pituitary disorders - Uncontrolled diabetes Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What makes DAC different from regular CJC-1295? The DAC (Drug Affinity Complex) is a maleimidopropionic acid (MPA) reactive group at the C-terminus of the peptide. Once injected, it forms a covalent bond with free cysteine residues on circulating serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. This extends the half-life from ~30 minutes (non-DAC) to ~8 days (DAC), allowing weekly instead of multiple-times-daily dosing. The trade-off is that DAC produces continuous, non-pulsatile GH elevation rather than the sharp, physiologic GH pulses of the non-DAC form. Why do most clinicians prefer the non-DAC version now? Three main reasons. First, the non-DAC form (MOD-GRF 1-29) preserves the body's natural pulsatile GH release pattern, which most endocrinologists believe is safer and more physiologic. Second, stacking MOD-GRF 1-29 with ipamorelin produces a 3-5x synergistic GH pulse that DAC cannot match (DAC doesn't have effective synergy with daily ghrelin-receptor agonists due to timing mismatch). Third, side effects — edema, carpal tunnel, glucose intolerance — are more common and more severe with sustained GH elevation from DAC. Weekly convenience is DAC's headline advantage; for most users, that doesn't outweigh the physiologic trade-offs. How long does DAC stay in my system after I stop? The half-life is approximately 8 days, so expect 3-4 weeks for full washout after discontinuation. IGF-1 levels gradually return to baseline over 4-6 weeks after the last dose. This long tail has practical implications: if you develop side effects, they resolve slowly; if you need to stop for surgery, plan 2-3 weeks ahead; if you want to switch to MOD-GRF 1-29, wait until full washout before starting the new protocol. It's a major reason some users prefer the more reversible non-DAC form. How much body composition change can I expect? Modestly improved, not dramatic. The benchmark is rhGH in healthy older adults (Blackman 2002, JAMA): 1-3 kg lean mass gain and 2-3 kg fat loss over 6 months. CJC-1295 with DAC produces somewhat less robust changes because it's a secretagogue (depending on pituitary response) rather than direct GH administration. Realistic expectations: 2-5% improvement in lean mass, 5-10% improvement in body fat over 3-6 months with consistent training and nutrition. If you're expecting dramatic physique changes from the peptide alone, you'll be disappointed. The peptide optimizes baseline physiology; you still need the training and diet. Do I need to inject on an empty stomach like with non-DAC? Not strictly. DAC's sustained release profile largely overrides postprandial somatostatin-mediated blunting. You can inject with or without food. However, many experienced users inject pre-bed 2+ hours after dinner, which aligns with natural nocturnal GH pulsing and is convenient for weekly dosing. The fasted-state rule is mandatory for non-DAC (MOD-GRF 1-29); for DAC it's a preference, not a requirement. Can I stack DAC with ipamorelin? Opinions vary. The pharmacologic rationale (synergistic GH pulse from dual pathway activation) is the same as for non-DAC + ipamorelin. However, because DAC already produces sustained GH elevation, adding daily ipamorelin may push pituitary capacity to its limit without proportional benefit, and some clinicians worry about compounding desensitization. A reasonable approach: if using DAC alone and IGF-1 is mid-range but benefit is modest, adding ipamorelin is worth trying. If DAC alone produces adequate IGF-1 rise, adding ipamorelin is probably redundant. Don't stack if you're also experiencing significant DAC-related side effects. Is DAC safe for long-term use? Honestly, the long-term safety data is limited. The Phase 1 trials were short (single-dose and multi-week). Clinical development halted at Phase 2. No multi-year surveillance data exists. Extrapolating from sermorelin (the FDA-approved analog with similar receptor activity), multi-year use appears tolerable in appropriately selected patients. The main long-term concerns are: (1) sustained elevated IGF-1 as a potential pro-tumorigenic signal (Renehan 2004 meta-analysis); (2) glucose dysregulation; (3) receptor desensitization. Use with quarterly lab monitoring, annual cancer screening, and willingness to stop or cycle if signals emerge. Don't assume long-term safety from short-term tolerability. What if I miss a weekly dose? Because DAC has an 8-day half-life, you have 2-3 days of grace built in — missing the weekly dose by a day or two doesn't substantially change your plasma levels. If you remember within 48 hours, take the missed dose and continue your normal schedule. If more than 48 hours late, skip the missed dose and take the next scheduled one — don't double-up. Chronic pattern of missed doses defeats the purpose and indicates DAC may not be the right protocol for you (consider the non-DAC form with daily reminders if adherence is an issue). Can I switch between DAC and non-DAC forms? Yes, but with a washout between. If transitioning DAC → MOD-GRF 1-29: wait 3-4 weeks after last DAC dose for full washout before starting MOD-GRF 1-29, to avoid receptor saturation and prolonged supraphysiologic IGF-1. If transitioning MOD-GRF 1-29 → DAC: you can start DAC within 48 hours of stopping MOD-GRF 1-29 (the non-DAC form clears quickly). Don't use both simultaneously — they target the same receptor and stacking is redundant and increases side effects without benefit. Most clinicians who use both forms do so in different phases of a protocol, not concurrently. ## Research Tools ### Peptide Calculator Reconstitution & syringe units https://www.bodyhackguide.co/tools/reconstitution ### Reconstitution Guide How to mix, step by step https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides ### Nasal Spray Calc mL per actuation https://www.bodyhackguide.co/tools/intranasal ### Half-Life Visualizer Decay curves https://www.bodyhackguide.co/tools/halflife ## Related Compounds ### CJC-1295 (Mod GRF 1-29) Growth Hormone / IGF-1 Axis Preclinical ### CJC-1295 with DAC ### GHRP-2 Growth Hormone / IGF-1 Axis Phase 2 ### GHRP-6 Growth Hormone / IGF-1 Axis Phase 2 ### Hexarelin Growth Hormone / IGF-1 Axis Phase 2 ### IGF-1 LR3 Growth Hormone / IGF-1 Axis Phase 2 ## Side-by-Side Comparisons Compare CJC-1295 with DAC head-to-head: mechanism, half-life, dosing, safety, and vendor prices. Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "CJC-1295 with DAC" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "CJC-1295 with DAC", "description": "CJC-1295 with DAC (Drug Affinity Complex) is a modified form of CJC-1295 that incorporates a maleimidopropionic acid (MPA) reactive group at the C-terminus. Once injected, this MPA group forms a covalent thioether bond with free cysteine residues on serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. The pharmacokinetic consequence is dramatic. Native GHRH has a half-life of <2 minutes. MOD-GRF 1-29 (CJC-1295 without DAC) has a half-life of ~30 minutes. CJC-1295 with DAC has a half-life of ~8 days and produces sustained IGF-1 elevation for up to 28 days after a single injection (Teichman et al., 2006, J Clin Endocrinol Metab). This makes DAC the weekly-dosing variant: one subcutaneous injection of 1-2 mg per week, typically on the same day each week. Convenience is its headline advantage over MOD-GRF 1-29's 2-3x daily injections. The trade-off is physiologic. DAC produces continuous, non-pulsatile GH elevation rather than the sharp pulses of natural secretion or MOD-GRF 1-29. In Teichman's Phase 1 trial, mean GH levels at 60 mcg/kg rose 2-10 fold above baseline and remained elevated continuously for 6-14 days after a single injection, with IGF-1 rising 1.5-3 fold and staying elevated for up to 28 days with repeated weekly dosing. This is an efficient way to raise IGF-1 but is not how the body normally operates. Clinical development was halted at Phase 2 — ConjuChem Biotechnologies did not publicly detail the reason, though industry commentary has pointed to concerns about sustained non-pulsatile GH elevation, insulin resistance, and the general challenges of bringing a GH-axis drug to market. Tesamorelin (a shorter-acting GHRH analog) became the FDA-approved GHRH analog for HIV-associated lipodystrophy instead. CJC-1295 with DAC is not FDA-approved and is used research-only or through compounding pharmacies. It is the less-favored of the two CJC-1295 forms in modern clinical protocols; most practitioners now prefer MOD-GRF 1-29 (without DAC) stacked with ipamorelin for the more physiologic pulsatile profile. See /compound/cjc-1295 for the non-DAC variant, and our Reconstitution Tool for injection math.", "url": "https://www.bodyhackguide.co/compound/cjc-1295-dac", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "34.99", "highPrice": "59.99", "priceCurrency": "USD", "offerCount": "6", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "34.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://www.vandl-labs.com/product/cjc-w-dac/?ref=choncho", "seller": { "@type": "Organization", "name": "VANDL Labs", "url": "https://www.vandl-labs.com/?ref=choncho" }, "name": "CJC-1295 with DAC 2mg vial" }, { "@type": "Offer", "price": "39.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://biomystlabs.com/product/cjc-w-dac-5mg/?ref=rxtkqorwv", "seller": { "@type": "Organization", "name": "BioMyst Labs", "url": "https://biomystlabs.com" }, "name": "CJC-1295 with DAC 5mg vial" }, { "@type": "Offer", "price": "44.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://biomystlabs.com/product/cjc-w-dac-5mg/?ref=rxtkqorwv", "seller": { "@type": "Organization", "name": "BioMyst Labs", "url": "https://biomystlabs.com" }, "name": "CJC-1295 with DAC 5mg vial" }, { "@type": "Offer", "price": "49.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://www.vandl-labs.com/product/cjc-w-dac/?ref=choncho", "seller": { "@type": "Organization", "name": "VANDL Labs", "url": "https://www.vandl-labs.com/?ref=choncho" }, "name": "CJC-1295 with DAC 5mg vial" }, { "@type": "Offer", "price": "59.00", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://ionpeptide.com/product/cjc-1295-with-dac-5mg/?ref=reddit15", "seller": { "@type": "Organization", "name": "Ion Peptide", "url": "https://ionpeptide.com" }, "name": "CJC-1295 with DAC 5mg vial" }, { "@type": "Offer", "price": "59.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/cjc-1295-drug-affinity-complex/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "CJC-1295 with DAC", "description": "CJC-1295 with DAC (Drug Affinity Complex) is a modified form of CJC-1295 that incorporates a maleimidopropionic acid (MPA) reactive group at the C-terminus. Once injected, this MPA group forms a covalent thioether bond with free cysteine residues on serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. The pharmacokinetic consequence is dramatic. Native GHRH has a half-life of <2 minutes. MOD-GRF 1-29 (CJC-1295 without DAC) has a half-life of ~30 minutes. CJC-1295 with DAC has a half-life of ~8 days and produces sustained IGF-1 elevation for up to 28 days after a single injection (Teichman et al., 2006, J Clin Endocrinol Metab). This makes DAC the weekly-dosing variant: one subcutaneous injection of 1-2 mg per week, typically on the same day each week. Convenience is its headline advantage over MOD-GRF 1-29's 2-3x daily injections. The trade-off is physiologic. DAC produces continuous, non-pulsatile GH elevation rather than the sharp pulses of natural secretion or MOD-GRF 1-29. In Teichman's Phase 1 trial, mean GH levels at 60 mcg/kg rose 2-10 fold above baseline and remained elevated continuously for 6-14 days after a single injection, with IGF-1 rising 1.5-3 fold and staying elevated for up to 28 days with repeated weekly dosing. This is an efficient way to raise IGF-1 but is not how the body normally operates. Clinical development was halted at Phase 2 — ConjuChem Biotechnologies did not publicly detail the reason, though industry commentary has pointed to concerns about sustained non-pulsatile GH elevation, insulin resistance, and the general challenges of bringing a GH-axis drug to market. Tesamorelin (a shorter-acting GHRH analog) became the FDA-approved GHRH analog for HIV-associated lipodystrophy instead. CJC-1295 with DAC is not FDA-approved and is used research-only or through compounding pharmacies. It is the less-favored of the two CJC-1295 forms in modern clinical protocols; most practitioners now prefer MOD-GRF 1-29 (without DAC) stacked with ipamorelin for the more physiologic pulsatile profile. See /compound/cjc-1295 for the non-DAC variant, and our Reconstitution Tool for injection math.", "lastReviewed": "2026-05-04T11:34:16.219+00:00", "url": "https://www.bodyhackguide.co/compound/cjc-1295-dac", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "CJC-1295 with DAC", "alternateName": [ "CJC w/ DAC", "CJC DAC" ], "description": "CJC-1295 with DAC (Drug Affinity Complex) is a modified form of CJC-1295 that incorporates a maleimidopropionic acid (MPA) reactive group at the C-terminus. Once injected, this MPA group forms a covalent thioether bond with free cysteine residues on serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. The pharmacokinetic consequence is dramatic. Native GHRH has a half-life of <2 minutes. MOD-GRF 1-29 (CJC-1295 without DAC) has a half-life of ~30 minutes. CJC-1295 with DAC has a half-life of ~8 days and produces sustained IGF-1 elevation for up to 28 days after a single injection (Teichman et al., 2006, J Clin Endocrinol Metab). This makes DAC the weekly-dosing variant: one subcutaneous injection of 1-2 mg per week, typically on the same day each week. Convenience is its headline advantage over MOD-GRF 1-29's 2-3x daily injections. The trade-off is physiologic. DAC produces continuous, non-pulsatile GH elevation rather than the sharp pulses of natural secretion or MOD-GRF 1-29. In Teichman's Phase 1 trial, mean GH levels at 60 mcg/kg rose 2-10 fold above baseline and remained elevated continuously for 6-14 days after a single injection, with IGF-1 rising 1.5-3 fold and staying elevated for up to 28 days with repeated weekly dosing. This is an efficient way to raise IGF-1 but is not how the body normally operates. Clinical development was halted at Phase 2 — ConjuChem Biotechnologies did not publicly detail the reason, though industry commentary has pointed to concerns about sustained non-pulsatile GH elevation, insulin resistance, and the general challenges of bringing a GH-axis drug to market. Tesamorelin (a shorter-acting GHRH analog) became the FDA-approved GHRH analog for HIV-associated lipodystrophy instead. CJC-1295 with DAC is not FDA-approved and is used research-only or through compounding pharmacies. It is the less-favored of the two CJC-1295 forms in modern clinical protocols; most practitioners now prefer MOD-GRF 1-29 (without DAC) stacked with ipamorelin for the more physiologic pulsatile profile. See /compound/cjc-1295 for the non-DAC variant, and our Reconstitution Tool for injection math.", "activeIngredient": "CJC-1295 with DAC", "administrationRoute": "Subcutaneous", "mechanismOfAction": "CJC-1295 with DAC has the same pharmacodynamic mechanism as the non-DAC variant (GHRH receptor agonism on pituitary somatotrophs) but radically different pharmacokinetics. Albumin conjugation - the central pharmacokinetic feature The MPA (maleimidopropionic acid) group is highly reactive toward free thiol groups Serum albumin contains one free cysteine (Cys-34) per molecule Within hours of SC injection, CJC-1295 DAC forms a covalent thioether bond with Cys-34 on serum albumin The conjugate circulates for the full albumin half-life (~20 days) Effective drug half-life: ~8 days (shorter than albumin because GHRH portion is slowly cleaved/metabolized) Sustained GHRH-receptor activation Because the albumin-bound conjugate keeps GHRH-active peptide in circulation for days, the pituitary GHRH receptor is continuously exposed to ligand rather than to brief, widely spaced pulses. Critically, this does not abolish pulsatile GH release: in the controlled pharmacodynamic work, pulsatile GH secretion persisted during continuous stimulation with CJC-1295 (Ionescu & Frohman, 2006, J Clin Endocrinol Metab). What shifts is the baseline - DAC raises trough (basal) and mean GH concentrations while the underlying pulse frequency is largely preserved. The practical consequences: Higher basal and mean GH, with pulsatility retained rather than eliminated A sustained IGF-1 plateau rather than the sharp IGF-1 swings of short-acting secretagogues A theoretical risk of partial receptor desensitization with chronic, continuous exposure Pharmacokinetic profile (Teichman Phase 1 data) Single 60 mcg/kg SC dose: GH levels: 2-10x baseline, sustained for 6-14 days IGF-1: 1.5-3x baseline, sustained for up to 28 days with repeated weekly dosing IGFBP-3 proportionally elevated No direct ghrelin-receptor activity DAC does not bind GHS-R1a. If stacking with ipamorelin is desired, the two must be dosed separately - DAC weekly, ipamorelin daily. Many practitioners skip ipamorelin when using DAC because the sustained GH elevation already approaches pituitary capacity. Downstream IGF-1 axis effects Hepatic JAK2/STAT5 signaling produces sustained IGF-1 mRNA transcription IGFBP-3 rises proportionally (binds 90% of circulating IGF-1) Free (bioactive) IGF-1 rises modestly Tissue IGF-1 (muscle, bone, cartilage) rises more substantially What's different vs MOD-GRF 1-29 (without DAC) This is why modern protocols favor the non-DAC form despite its inconvenience.", "dosageForm": "vial", "legalStatus": "Not approved for human use (research chemical)", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What makes DAC different from regular CJC-1295?", "acceptedAnswer": { "@type": "Answer", "text": "The DAC (Drug Affinity Complex) is a maleimidopropionic acid (MPA) reactive group at the C-terminus of the peptide. Once injected, it forms a covalent bond with free cysteine residues on circulating serum albumin, effectively turning the small peptide into a long-circulating albumin-peptide conjugate. This extends the half-life from ~30 minutes (non-DAC) to ~8 days (DAC), allowing weekly instead of multiple-times-daily dosing. The trade-off is that DAC produces continuous, non-pulsatile GH elevation rather than the sharp, physiologic GH pulses of the non-DAC form." } }, { "@type": "Question", "name": "Why do most clinicians prefer the non-DAC version now?", "acceptedAnswer": { "@type": "Answer", "text": "Three main reasons. First, the non-DAC form (MOD-GRF 1-29) preserves the body's natural pulsatile GH release pattern, which most endocrinologists believe is safer and more physiologic. Second, stacking MOD-GRF 1-29 with ipamorelin produces a 3-5x synergistic GH pulse that DAC cannot match (DAC doesn't have effective synergy with daily ghrelin-receptor agonists due to timing mismatch). Third, side effects — edema, carpal tunnel, glucose intolerance — are more common and more severe with sustained GH elevation from DAC. Weekly convenience is DAC's headline advantage; for most users, that doesn't outweigh the physiologic trade-offs." } }, { "@type": "Question", "name": "How long does DAC stay in my system after I stop?", "acceptedAnswer": { "@type": "Answer", "text": "The half-life is approximately 8 days, so expect 3-4 weeks for full washout after discontinuation. IGF-1 levels gradually return to baseline over 4-6 weeks after the last dose. This long tail has practical implications: if you develop side effects, they resolve slowly; if you need to stop for surgery, plan 2-3 weeks ahead; if you want to switch to MOD-GRF 1-29, wait until full washout before starting the new protocol. It's a major reason some users prefer the more reversible non-DAC form." } }, { "@type": "Question", "name": "How much body composition change can I expect?", "acceptedAnswer": { "@type": "Answer", "text": "Modestly improved, not dramatic. The benchmark is rhGH in healthy older adults (Blackman 2002, JAMA): 1-3 kg lean mass gain and 2-3 kg fat loss over 6 months. CJC-1295 with DAC produces somewhat less robust changes because it's a secretagogue (depending on pituitary response) rather than direct GH administration. Realistic expectations: 2-5% improvement in lean mass, 5-10% improvement in body fat over 3-6 months with consistent training and nutrition. If you're expecting dramatic physique changes from the peptide alone, you'll be disappointed. The peptide optimizes baseline physiology; you still need the training and diet." } }, { "@type": "Question", "name": "Do I need to inject on an empty stomach like with non-DAC?", "acceptedAnswer": { "@type": "Answer", "text": "Not strictly. DAC's sustained release profile largely overrides postprandial somatostatin-mediated blunting. You can inject with or without food. However, many experienced users inject pre-bed 2+ hours after dinner, which aligns with natural nocturnal GH pulsing and is convenient for weekly dosing. The fasted-state rule is mandatory for non-DAC (MOD-GRF 1-29); for DAC it's a preference, not a requirement." } }, { "@type": "Question", "name": "Can I stack DAC with ipamorelin?", "acceptedAnswer": { "@type": "Answer", "text": "Opinions vary. The pharmacologic rationale (synergistic GH pulse from dual pathway activation) is the same as for non-DAC + ipamorelin. However, because DAC already produces sustained GH elevation, adding daily ipamorelin may push pituitary capacity to its limit without proportional benefit, and some clinicians worry about compounding desensitization. A reasonable approach: if using DAC alone and IGF-1 is mid-range but benefit is modest, adding ipamorelin is worth trying. If DAC alone produces adequate IGF-1 rise, adding ipamorelin is probably redundant. Don't stack if you're also experiencing significant DAC-related side effects." } }, { "@type": "Question", "name": "Is DAC safe for long-term use?", "acceptedAnswer": { "@type": "Answer", "text": "Honestly, the long-term safety data is limited. The Phase 1 trials were short (single-dose and multi-week). Clinical development halted at Phase 2. No multi-year surveillance data exists. Extrapolating from sermorelin (the FDA-approved analog with similar receptor activity), multi-year use appears tolerable in appropriately selected patients. The main long-term concerns are: (1) sustained elevated IGF-1 as a potential pro-tumorigenic signal (Renehan 2004 meta-analysis); (2) glucose dysregulation; (3) receptor desensitization. Use with quarterly lab monitoring, annual cancer screening, and willingness to stop or cycle if signals emerge. Don't assume long-term safety from short-term tolerability." } }, { "@type": "Question", "name": "What if I miss a weekly dose?", "acceptedAnswer": { "@type": "Answer", "text": "Because DAC has an 8-day half-life, you have 2-3 days of grace built in — missing the weekly dose by a day or two doesn't substantially change your plasma levels. If you remember within 48 hours, take the missed dose and continue your normal schedule. If more than 48 hours late, skip the missed dose and take the next scheduled one — don't double-up. Chronic pattern of missed doses defeats the purpose and indicates DAC may not be the right protocol for you (consider the non-DAC form with daily reminders if adherence is an issue)." } }, { "@type": "Question", "name": "Can I switch between DAC and non-DAC forms?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, but with a washout between. If transitioning DAC → MOD-GRF 1-29: wait 3-4 weeks after last DAC dose for full washout before starting MOD-GRF 1-29, to avoid receptor saturation and prolonged supraphysiologic IGF-1. If transitioning MOD-GRF 1-29 → DAC: you can start DAC within 48 hours of stopping MOD-GRF 1-29 (the non-DAC form clears quickly). Don't use both simultaneously — they target the same receptor and stacking is redundant and increases side effects without benefit. Most clinicians who use both forms do so in different phases of a protocol, not concurrently." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```